Results 71 to 80 of about 2,891 (162)

A CRM1 Inhibitor Alleviates Cardiac Hypertrophy and Increases the Nuclear Distribution of NT-PGC-1α in NRVMs

Frontiers in Pharmacology, 2019
Chromosomal maintenance 1 (CRM1) inhibitors display antihypertrophic effects and control protein trafficking between the nucleus and the cytoplasm. PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1alpha) is a type of transcriptional ...
Zuheng Liu, Zuheng Liu, Haiping Tian, Haiping Tian, Haiping Tian, Jinghai Hua, Jinghai Hua, Wanqiang Cai, Wanqiang Cai, Yujia Bai, Yujia Bai, Qiong Zhan, Qiong Zhan, Wenyan Lai, Wenyan Lai, Qingchun Zeng, Qingchun Zeng, Hao Ren, Hao Ren, Dingli Xu, Dingli Xu   +20 more
doaj   +1 more source

US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma

ClinicoEconomics and Outcomes Research, 2020
Jan Bassali, 1 Ian Gopal Gould, 2 James A Kaye, 3 Deirdre Mladsi, 4 Jyotsna Mehta 5 1Global Medical and Scientific Affairs Department , Karyopharm Therapeutics, Newton, MA, 02459, USA; 2Research Health Economy, RTI Health Solutions, Research Triangle ...
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J   +4 more
doaj  

Retreatment with talquetamab and pomalidomide in triple‐class–BCMA–GPRC5D refractory myeloma

British Journal of Haematology, Volume 209, Issue 1, Page 320-323, July 2026.
Kian J. Rahbari, Gliceida M. Galarza Fortuna, Bhagirathbhai Dholaria, Douglas W. Sborov, Muhamed Baljevic   +4 more
wiley   +1 more source

Responses to selinexor in multiple myeloma [PDF]

Nature Reviews Clinical Oncology, 2019
openaire   +2 more sources

Structure-Based Virtual Screening and Mechanistic Characterization of Methotrexate and Selinexor as Potent Anti-Melanogenic Agents via Multi-Pathway Suppression of MITF. [PDF]

Cells
Zhang Z, Li H, Shi Z, Bai X, Yin P, Yang L.   +5 more
europepmc   +1 more source

Targeting the nuclear export receptor exportin-1 in acute myeloid leukaemia: From biology to clinical translation. [PDF]

Clin Transl Med
Liu Y, Yun X, Ding W, Li S, Liu H.
europepmc   +1 more source

Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study. [PDF]

Blood Adv
Ali H, Mohan S, Kishtagari A, Prchal JT, Maher K, Chai Y, Gudi G, Taverna P, Mark T, Tantravahi SK.   +9 more
europepmc   +1 more source

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. [PDF]

Br J Haematol
Delimpasi S, Špička I, Butler JP, Stevens DA, Mesa MG, Bygrave C, Merlo GM, la Porte C, Dimopoulos MA.   +8 more
europepmc   +1 more source

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape. [PDF]

ESMO Open
Gay F, Buda G, Petrucci MT, Bolli N, Cea M, Derudas D, Mangiacavalli S, Montefusco V, Antonioli E, Barilà G, Basso M, Bertazzoni P, Bertuglia G, Bianco R, Carlisi M, Giudice MLD, Della Pepa R, Fazio F, Franceschini L, Furlan A, Gozzetti A, Liberatore C, Mancuso K, Martino EA, Mele G, Monaco F, Morè S, Paris L, Pavan L, Pezzatti S, Rago A, Ribolla R, Roncato R, Rossini B, Sgherza N, Vassallo F, Vincelli DI, Za T, Musto P, Zamagni E.   +39 more
europepmc   +1 more source

The Evolving Landscape of Systemic Therapy for Liposarcoma. [PDF]

Cancers (Basel)
Kim HK, Sarkari A, Chow WA.
europepmc   +1 more source